OVERVIEW

RME Hot Seat: Immunotherapy for Multiple Myeloma is organized by RedMedEd.

Release date:1/4/2021
Expiration date:1/4/2022

Target Audience: This activity has been designed to meet the educational needs oncology nurses, advanced oncology certified nurse practitioners, and other health care providers involved in the care of oncology patients.

Overview:
The number and type of treatments for multiple myeloma continue to expand rapidly. The emergence of several new immunotherapy options holds particular promise for patients with relapsed/refractory myeloma, but effectively integrating these approaches into practice remains a significant challenge.

Developed for oncology nurses and advanced practitioners, this RME Hot Seat provides a virtual Q&A with a panel of experts who field a range of questions on the use of antibody-based therapies, bispecific T-cell engagers, chimeric antigen receptor T–cell therapy, and other new and emerging immunotherapeutic options for myeloma patient care.

Learning Objectives:
At the conclusion of this activity, participants should be better able to:
• Distinguish between mechanisms of action and safety profiles of multiple myeloma immunotherapies
• Evaluate recent clinical advances in the use of existing and emerging immunotherapies and their potential implications for clinical practice